Psychiatry · PTSDTrial Updateclinicalmid-term

Study on Predictors of PTSD Relapse in Children and Families

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 12:30:50 PM

Assessment confidence: 89% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

This study aims to identify predictors of PTSD relapse, which is critical for developing targeted interventions in mental health. The findings could significantly influence treatment strategies and competitive positioning for companies focused on PTSD therapies. Regulatory context from FDA (FDA AP — CHILDREN'S CLARITIN (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (13 high-relevance).

Strategic Assessment

Insights from this study may lead to the development of targeted interventions for PTSD, influencing portfolio strategies for companies focused on mental health therapies. The strongest clinical anchor is Identification of Markers of Post-Traumatic Stress Disorder (PTSD) Relapse (ClinicalTrials.gov), sub-indication match (ild). In ild, 8 regulatory and 0 competitive items passed relevance filtering for mental health therapy companies.

Competitive Pressure

The most relevant competitive pressure comes from Understanding predictors of PTSD relapse could inform treatment strategies and improve patient outcomes, impacting competitive positioning in the mental health space..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CHILDREN'S CLARITIN (SUPPL) (FDA). Sub-indication match (ild); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. New biomarkers could lead to changes in treatment guidelines and regulatory submissions, impacting compliance and approval processes for PTSD therapies.

Key Risks

Elevated medium regulatory exposure for mental health therapy companies could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, the identification of biomarkers could enhance treatment offerings, potentially increasing market share for companies that adapt their portfolios to include these insights.
Insights from this study may lead to the development of targeted interventions for PTSD, influencing portfolio strategies for companies focused on mental health therapies.

What Would Change This Assessment

This becomes more urgent if Monitor results for potential biomarkers that could be leveraged in future PTSD treatment protocols.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CHILDREN'S CLARITIN (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CHILDREN'S CLARITIN (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CHILDREN'S ALLEGRA HIVES (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CHILDREN'S ADVIL (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CHILDREN'S ALLEGRA HIVES (SUPPL)
FDAhigh relevance
Sub-indication match (ild); Regulatory pathway relevance (nda)
FDA document
View source
Lower dose needle-free allergy treatment approved for younger children
MHRAhigh relevance
Sub-indication match (ild)
FDA document
View source
FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children
FDAhigh relevance
Sub-indication match (ild)
FDA document
View source

Identification of Markers of Post-Traumatic Stress Disorder (PTSD) Relapse
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
A Trial Testing Two-way SMS Platform to Recognize and Prevent Wasting Among HIV-infected and HIV-exposed Uninfected Children in Kenya
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
Affirmative Psychotherapy for Sexual Minority Women's Mental and Behavioral Health
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

No evidence in this category.

Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

mental health therapy companies

Commercial impact

medium

If successful, the identification of biomarkers could enhance treatment offerings, potentially increasing market share for companies that adapt their portfolios to include these insights.

Regulatory impact